Stockscreener 앱 받기
2.31
7.44%
0.16
시장 영업 전:
2.33
0.02
+0.87%
In 8 Bio Inc 주식(INAB)의 최신 뉴스
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Is Tourmaline Bio Inc. stock ready for a breakoutFree Alpha Driven Watchlist With Alerts - Newser
MUSTANG BIO, INC. SEC 10-Q Report - TradingView
REPEATTevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions - uk.finance.yahoo.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KALA BIO, Inc. SEC 10-Q Report - TradingView
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioVie Inc. Announces Pricing of $12 Million Public Offering - The Manila Times
Gossamer Bio Expands Team with 168,750 Share Options Grant at $2.16 Exercise Price - Stock Titan
INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire
Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth - Stock Titan
Nuvation Bio Reports 1,043% YoY Sales Growth, Exceeds Revenue Estimates with $4.8 Million in GAAP Revenue - AInvest
Palisade Bio Reports 100% Clinical Response in Phase 1b - GlobeNewswire
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
New Lung Cancer Drug IBTROZI Gains FDA Approval, Reaches 70 Patients in First 7 Weeks - Stock Titan
How sentiment analysis helps forecast Instil Bio Inc.Insider Strategy for High Conviction Picks - Newser
Can technical indicators confirm Belite Bio Inc Depositary Receipt’s reversalFree Weekly Return Pick Forecast Reports - Newser
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc. - Bluefield Daily Telegraph
7 Dividend Stocks for 2025 — Some Pay Over 8%, Some Just Refuse to Die - The Globe and Mail
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
Q32 Bio Secures FDA Fast Track for Alopecia Treatment as Phase 2 Trial Advances with $54.8M Runway - Stock Titan
Climb Bio Inc. stock daily chart insightsFree ROI Driven Equity Selection With Safety - Newser
Adicet Bio's Gamma Delta T Cell Therapy Updates Coming at Major Growth Conference - Stock Titan
INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan
What drives Upstream Bio Inc. stock priceDynamic profit expansion - Jammu Links News
Should I hold or sell Third Harmonic Bio Inc. stock in 2025Unlock expert market analysis instantly - Jammu Links News
Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - jammulinksnews.com
How many analysts rate bluebird bio Inc. as a “Buy”Low Risk Alerts Backed By Experts - Jammu Links News
10 Penny Stocks That Will Skyrocket - Insider Monkey
What makes INmune Bio Inc. stock price move sharplyBreakout Stocks Tracker With High Returns - Jammu Links News
Nasdaq Compliance Regained: Passage Bio Stock Price Meets Minimum Requirement - AInvest
INmune Bio to Present Q2 2025 Financial Results and Key Clinical-Stage Updates on August 7 - Stock Titan
What are the latest earnings results for Climb Bio Inc.Advanced Screener Growth Plan For Fast Growth - Jammu Links News
How Palisade Bio Inc. stock performs during market volatilityPattern Recognition Based Market Move Prediction - Newser
What institutions are buying Korro Bio Inc. stock nowMarket Stability and Long-Term Growth Outlook - Newser
Is 2seventy bio Inc. forming a reversal patternFree Weekly Growth Stock Entry Point Alerts - Newser
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - Jammu Links News
Is 2seventy bio Inc. stock overvalued or undervaluedOverwhelming profit margins - jammulinksnews.com
What are analysts’ price targets for Korro Bio Inc. in the next 12 monthsBreakout portfolio performance - Jammu Links News
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - uk.finance.yahoo.com
Moving Average Trends for 2seventy bio Inc. Stock: What They IndicateFree Professional Trading Signals - Newser
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
What drives INmune Bio Inc. stock priceSignificant capital appreciation - PrintWeekIndia
Adicet Bio Expands Autoimmune Disease Trial: First Systemic Sclerosis Patient Receives Novel T Cell Therapy - Stock Titan
Global Oncology Leader Nuvation Bio Sets Q2 Earnings Call: Latest Cancer Treatment Progress - Stock Titan
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million - GlobeNewswire
What drives Adicet Bio Inc. stock priceFree Market Dynamics Reports - Jammu Links News
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
What analysts say about 2seventy bio Inc. stockExceptional return forecasts - Autocar Professional
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
What drives Mustang Bio Inc. stock priceMarket-leading growth rates - jammulinksnews.com
0.24%
3.39%
자본화:
|
볼륨(24시간):